|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Histogenics Corporation
| | | Phone: | (781) 547-7900 | Fax: | (781) 547-4452 | Year Established: | 2000 | Ticker: | HSGX | Exchange: | NASDAQ | Main Contact: | Adam Gridley, President & CEO | | Other Contacts: | Donald Haut, Ph.D., CBO Harris Shuman, VP of Finance Peter Hamilton, VP of Operations & Engineering E. Lynne Kelley, M.D., FACS, CMO Caroline Dugopolski, VP of Technical Operations Stephen Kennedy, Executive VP & COO Jon Lieber, CFO
| | Company Description | Histogenics is a leading regenerative medicine company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo. Histogenics’ first investigational product candidate, NeoCart is designed to treat cartilage defects in the knee and is currently in Phase 3 clinical development. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage. As a result, NeoCart is the only product in development or on the market with a one-year primary superiority endpoint as compared to the standard of care. There are more than 500,000 or more knee cartilage procedures in the United States each year, with many healthy active adults avoiding treatment as they seek other alternatives. | |
|
|
|
|
|